ROCK Mediates Phorbol Ester-induced Apoptosis in Prostate Cancer Cells via p21^{Cip1} Up-regulation and JNK^{**}

Liqing Xiao^{1, 1}, Masumi Eto^{2, 2}, and Marcelo G. Kazanietz^{2, 2}

From the ^1Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160 and the ^2Department of Molecular Physiology and Biophysics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

It is established that androgen-dependent prostate cancer cells undergo apoptosis upon treatment with phorbol esters and related analogs, an effect primarily mediated by PKC\(\delta\). Treatment of LNCaP prostate cancer cells with phorbol 12-myristate 13-acetate (PMA) causes a strong and sustained activation of RhoA and its downstream effector ROCK (Rho kinase) as well as the formation of stress fibers. These effects are impaired in cells subjected to PKC\(\delta\) RNA interference depletion. Functional studies revealed that expression of a dominant negative RhoA mutant or treatment with the ROCK inhibitor Y-27632 inhibits the apoptotic effect of PMA in LNCaP cells. Remarkably, the cytoskeleton inhibitors cytochalasin B and blebbistatin blocked not only PMA-induced apoptosis but also the activation of JNK, a mediator of the cell death effect by the phorbol ester. In addition, we found that up-regulation of the cell cycle inhibitor p21^{Cip1} is required for PMA-induced apoptosis and that inhibitors of ROCK or the cytoskeleton organization prevent p21^{Cip1} induction. Real time PCR analysis and reporter gene assay revealed that PMA induces p21^{Cip1} transcriptionally in a ROCK- and cytoskeleton-dependent manner. p21^{Cip1} promoter analysis revealed that PMA induction is dependent on Sp1 elements in the p21^{Cip1} promoter but independent of p53. Taken together, our studies implicate ROCK-mediated up-regulation of p21^{Cip1} and the cytoskeleton in PKC\(\delta\)-dependent apoptosis in prostate cancer cells.

The protein kinase C (PKC)^3 family of serine-threonine kinases has been widely implicated in the control of mitogenesis, cell survival, apoptosis, and differentiation. Based on their different structural organization and biochemical regulation by lipids and calcium, PKCs have been classified into three groups: classical or conventional (PKC\(\alpha\), \(\beta\), and \(\gamma\)), novel (PKC\(\delta\), \(\epsilon\), \(\eta\), and \(\theta\)), and atypical PKCs (PKC\(\zeta\) and \(\lambda\)). Both conventional PKCs and novel PKCs are the target for the phorbol esters, natural products that mimic the action of the lipid second messenger diacylglycerol (1, 2). Despite their well-characterized tumor promoter activity, phorbol esters cause dissimilar effects, since they can either stimulate proliferation and survival or, conversely, induce cell growth arrest or trigger apoptotic cell death, depending on the cell type (2, 3). Such diversity relates primarily to the differential expression of PKC isoforms according to cell type as well as to the great divergence in the signaling events modulated by individual PKCs. One of the key PKC isoforms implicated in negative growth regulation is PKC\(\delta\). Work from several laboratories, including ours, established that PKC\(\delta\) modulates the transition from \(G_1\) to \(S\) phase of the cell cycle by controlling the phosphorylation status of retinoblastoma (4 – 6). In bronchoalveolar adenocarcinoma cells, activation of PKC\(\delta\) in early \(G_1\) leads to \(G_1/S\) arrest through the induction of p21^{Cip1} at a transcriptional level (4).

Among the few cell types that undergo apoptosis in response to phorbol esters, androgen-responsive prostate cancer cells have been one of the best characterized models. Phorbol 12-myristate 13-acetate (PMA) triggers an apoptotic response in androgen-dependent prostate cancer cells, including LNCaP, C4-2, and CWR22-Rv1 cells (7–9). The mechanisms underlying the cell death effect of phorbol esters in prostate cancer cells are only partially understood, but they seem to involve the p21^{Cip1}/retinoblastoma pathway (10). Our previous studies established that this effect is primarily mediated by PKC\(\delta\), and subsequent analysis revealed that this kinase promotes the activation of the extrinsic apoptotic cascade via an autocrine mechanism. PMA promotes the secretion of death factors from LNCaP cells via PKC\(\delta\), including TNF\(\alpha\) and TRAIL, and the released factors promote cell death via activation of JNK and p38 MAPK cascades (11, 12).

The mammalian Rho GTPases comprise \(\geq 20\) proteins, among which Rac1, Cdc42, and RhoA have been the most widely studied. These small G-proteins have been established as important mediators of receptor signaling and control a variety of cellular functions related to cell division and morphology. Upon receptor activation, Rho GTPases dissociate from Rho guanine nucleotide dissociation inhibitors (Rho-GDI), allowing Rho guanine nucleotide exchange factors (Rho-GEFs) to switch GDP by GTP and Rho activation (13). Members of the Rho family were originally established as key regulators of cytoskeletal organization in response to extracellular growth factors. Studies over the past few years have revealed that Rho GTPases also play crucial roles in diverse cellular events, such as transcriptional regulation, cell cycle control, endocytosis,
Rho and ROCK as Mediators of PMA-induced Apoptosis

differentiation, and apoptosis (13, 14). Recently, growing attention has been drawn toward the emerging role of the cytoskeleton in the modulation of apoptosis. RhoA, predominantly through its effectors ROCKI and ROCKII serine/threonine kinases, regulates the phosphorylation of multiple downstream targets, including myosin light chain and LIM kinases (15, 16), which control actin cytoskeleton assembly and cell contractility. It has been shown that caspase-3-mediated ROCKI activation is both necessary and sufficient for the formation of membrane blebs and nuclear disintegration in apoptotic cells (17, 18). In some cell types, ROCK is involved in the intracellular signaling that initiates apoptosis, such as caspase-8, caspase-10, and caspase-3 activation (19) or modulates the transcription of the proapoptotic proteins, such as Bax (20).

Emerging evidence implicated Rho GTPases as mediators of PKC signaling. For example, the decreased invasiveness of PKC-depleted head and neck squamous carcinoma cells is associated with a corresponding inactivation of RhoA and RhoC GTPases (21). PKCs can modulate Rho function through either Rho-GEF activation or Rho-GDI inactivation (22, 23) or by direct association to Rho (24). However, it is not known whether Rho or its downstream effectors are implicated in PMA-induced apoptosis in prostate cancer cells.

In the present study, we show that PMA causes a strong and sustained activation of Rho and the formation of stress fibers via PKCζ. Notably, inhibition of Rho or its downstream effector ROCK impairs apoptosis triggered by PKC activation, suggesting a crucial role for Rho and ROCK downstream of PKCζ. We also found that ROCK mediates the induction of p21Cip1, a necessary event for apoptosis induced by PMA. All of these effects depend on the integrity of the cytoskeleton, since agents that disrupt cytoskeleton organization markedly impaired apoptosis, JNK activation, and p21Cip1 induction by PMA.

EXPERIMENTAL PROCEDURES

Materials—PMA was purchased from LC Laboratories (Woburn, MA). 4’,6-Diamidino-2-phenylindole, cytochalasin, and blebbistatin were obtained from Sigma. Y-27632 and SP600125 were purchased from Calbiochem. GF 109203X was purchased from Biomol (Plymouth Meeting, PA). Rhodamine-phalloidin was purchased from Molecular Probes, Inc. (Eugene, OR). Microcystin-LR was purchased from Alexis Biochemicals (San Diego, CA). Cell culture reagents and media were from ATCC (Manassas, VA).

Cell Culture—LNCaP, C4-2, and CWR22 human prostate cancer cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin (100 units/ml)-streptomycin (100 μg/ml) at 37 °C in a humidified 5% CO₂ atmosphere.

Adenoviral Infections—LNCaP cells in 6-well plates (~70% confluence) growing in RPMI 1640 medium supplemented with 2% fetal bovine serum were infected with an adenovirus (AdV) for a dominant negative RhoA mutant N19-RhoA or a GFP control AdV for 14 h at a multiplicity of infection of 10 plaque-forming units/cell. After removal of the AdV by extensive washing, cells were incubated for an additional 24 h in RPMI 1640 medium supplemented with 10% fetal bovine serum. Expression of the recombinant protein remained stable throughout the duration of the experiment, as detected by Western blotting (data not shown).

Western Blot Analysis—Cells were harvested into lysis buffer containing 50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, and 5% β-mercaptoethanol. Protein determinations were performed with the Bio-Rad DC protein assay according to the instructions provided by the manufacturer. Equal amounts of protein (20 μg/lane) were subject to SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% milk or 5% bovine serum albumin in 0.05% Tween 20, phosphate-buffered saline and then incubated with the first antibody overnight at 4 °C. Membranes were washed three times with 0.05% Tween 20 in PBS and then incubated with anti-mouse or anti-rabbit secondary antibodies conjugated to horseradish peroxidase (1:3000; Bio-Rad). Bands were visualized with the ECL Western blotting detection system.

The following primary antibodies were used: anti-PKCζ (Transduction Laboratories, Lexington, KY); anti-RhoA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); anti-actin (Sigma); anti-p21Cip1, anti-phospho-JNK, anti-JNK, anti-phospho-p38 MAPK, and anti-p38 MAPK (Cell Signaling Technology, Beverly, MA); and anti-phospho-MYPT1 (myosin phosphatase target subunit 1)-Thr⁵⁸⁴ (Millipore, Billerica, MA). All antibodies were used at a 1:1000 dilution except for the anti-actin antibody, which was used at a 1:20,000 dilution.

Apoptosis Assays—The incidence of apoptosis was determined as we previously described (7). Briefly, cells were stained with 4’,6-diamidino-2-phenylindole (Sigma). Cells were trypsinized, mounted on glass slides, fixed in 70% ethanol, and then stained for 20 min with 1 mg/ml 4’,6-diamidino-2-phenylindole. Apoptosis was characterized by chromatin condensation and fragmentation when examined by fluorescence microscopy. The incidence of apoptosis in each preparation was analyzed by counting ~300 cells.

RNA Interference (RNAi)—21-bp double-stranded RNAs were purchased from Dharmacon Research, Inc. (Dallas, TX) or Ambion (Austin, TX) and transfected into LNCaP cells using the Amaxa Nucleofector (Amaxa Biosystems, Gaithersburg, MD) following the instructions provided by the manufacturer. Experiments were performed 48 h after transfection. The following targeting sequences were used: CCATGAGTTT-ATCGCCACCTT (PKCζ 1), CCATGTATCCCTGAT-GGA (PKCζ 2), AACATACTGGCCTGGACTGTT (p21Cip1 1), ATGCCTACGACCTTTCTCTTT (p21Cip1 2), GTAGTGCTCTAGGTTTTG (Sp1 1), and GGTCATTTCTTTGCT-CATG (Sp1 2). As a control RNAi, we used the Silencer® negative control 7 siRNAi (Ambion).

Real Time PCR—RNA was extracted using TRIZol (Invitrogen). Two μg of RNA/sample were reverse transcribed using the First-Strand cDNA synthesis kit (Amersham Biosciences) following the instructions provided by the manufacturer. PCR primers and fluorogenic probes for p21Cip1 were purchased from Applied Biosystems. The probes were 5’-end-labeled with 6-carboxyfluorescein. Each PCR amplification was performed in a total volume of 12.5 μl, containing 6.25 μl of 2× TaqMan Universal PCR Master Mix (Applied Biosystems), commercial target primers (300 nM), the fluorescent probe (200 nM),
and 1 μl of cDNA, using an ABI PRISM 7700 detection system. PCR product formation was continuously monitored using Sequence Detection System software version 1.7 (Applied Biosystems). The 6-carboxyfluorescein signal was normalized to endogenous 18 S RNA.

**Plasmid Transfections and Promoter Analyses—**LNCaP cells (1.5 × 10⁶ cells) were transfected with 2 μg of p21C⁹⁹⁹; firefly luciferase reporter vectors (25) using the Amaza Nucleofector. A Renilla luciferase expression vector (100 ng, pRL-TK; Promega, Madison, WI) was co-transfected for normalization of transfection efficiency. Forty-eight h after transfection, cells were stimulated with PMA and lysed. Cell extracts were subject to luciferase determination using the Dual-Luciferase reporter assay system (Promega).

**Confocal Microscopy and Phalloidin Staining—**Cells were washed twice with PBS, fixed in 4% paraformaldehyde in PBS for 10 min, and washed briefly with PBS. For phalloidin staining, cells were blocked in 5% bovine serum albumin in PBS for 30 min. Cells were stained with phalloidin (Molecule Probes) in PBS containing 1% bovine serum albumin for 10 min, and washed briefly with PBS. For phalloidin staining, we used the ROCK Activity Immunoblot Kit (Cell Biolabs, Inc.). Briefly, cells were washed twice with ice-cold PBS and lysed with an immunoprecipitation buffer (50 mM Tris-HCl, pH 7.2, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM NaCl, and 10 mM MgCl₂). The supernatant was collected and incubated with glutathione S-transferase-ROCK binding domain (20 μg) for 60 min at 4 °C. Beads were washed with 50 mM Tris-HCl buffer containing 1% Triton X-100, 150 mM NaCl, 10 mM MgCl₂, boiled with SDS sample buffer with 5% mercaptoethanol, and subjected to Western blot.

**ROCK Kinase Assays—**ROCK kinase activity was measured using a rabbit anti-phospho-Thr³⁵⁰-MYPT1 antibody (27). Second, we used the ROCK Activity Immunoblot Kit (Cell Biolabs, Inc.). Briefly, cells were washed twice with ice-cold PBS and lysed with an immunoprecipitation buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM MgCl₂, 10 mM NaF, 5% glycerol, 1% Nonidet P-40, 1 mM dithiothreitol, 1 mM EGTA, 1 μM microcystin-LR, and mixture proteinase inhibitor). Cell lysates were centrifuged at 10,000 rpm for 10 min to remove insoluble debris. Supernatants were transferred to fresh tubes, precleared with protein G-Sepharose (Invitrogen) beads for 15 min, and incubated with an anti-ROCK antibody (Santa Cruz Biotechnology) for 40 min. The antibody-ROCK complexes were pulled down with protein G-Sepharose beads (20 min). Beads were washed three times in immunoprecipitation buffer and incubated with the kinase reaction mixture (final volume = 25 μl) that included 0.25 μg of rMYPT1 and 200 μg of ATP, following the protocol indicated by the manufacturer. Samples were subjected to Western blot, and rMYPT1 phosphorylation was determined using a rabbit anti-phospho-Thr³⁵⁰-MYPT1 antibody.

**Enzyme-linked Immunosorbent Assay—**TNFα levels were determined by ELISA (Pepro Tech Inc.), essentially as described previously (11). Briefly, 100 μl of conditioned medium (CM) were added into each well and incubated overnight at 4 °C. Subsequently, 100 μl of biotin-labeled anti-TNFα antibody (0.25 μg/ml) was added for 2 h at room temperature. Bound antibody was detected by incubation with peroxidase-labeled avidine and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) from Sigma, and absorbance was measured at 450 nm. Nonspecific binding was blocked with 1% bovine serum albumin in PBS.

**RESULTS**

**PMA Induces the Activation of Rho and ROCK in LNCaP Prostate Cancer Cells—**Phorbol esters induce a strong apoptotic response in LNCaP cells. This effect is mediated primarily by PKCδ, which upon activation stimulates the release of death factors and the extrinsic apoptotic cascade (11). Since PKC isozymes have been shown to regulate Rho GTPases, and Rho has been implicated in apoptosis triggered by diverse stimuli, we speculated that this small G-protein could be involved in phorbol ester-induced apoptosis in prostate cancer cells. To address this issue, we first examined if PMA could promote the activation of RhoA in LNCaP cells. Using a pull-down assay, we found that treatment with PMA (100 nM) caused a robust and sustained elevation in Rho-GTP levels in LNCaP cells, which persisted for at least 3 h poststimulation (Fig. 1A). RhoA activation by PMA was blocked by pretreatment of LNCaP cells with the pan-PKC inhibitor GF 109203X (Fig. 1B), suggesting that it is mediated by PKC isozymes and not other phorbol ester receptors unrelated to PKC (2).

Since ROCK is a main Rho effector, we determined the effect of PMA on ROCK activation in LNCaP cells. As a first approach, we examined the phosphorylation of the ROCK substrate MYPT1, using a specific phosphoantibody against Thr³⁵⁰-MYPT1, a well-established ROCK phosphorylation site (27). As shown in Fig. 1C (left), PMA induces a marked MYPT1 phosphorylation, which peaks at 15 min and is sustained for at least 1 h. ROCK activation can also be observed in C4-2 and CRW22 androgen-dependent prostate cancer cells (Fig. 1C, right).

Next, we examined ROCK activation using an immunoprecipitation assay. Endogenous ROCK was pulled down from LNCaP cells treated with PMA (100 nM, 0–15 min), and ROCK activity was determined using an in vitro kinase assay using a substrate the recombinant fragment of MYPT1 that comprises the ROCK phosphorylation site (amino acids 654–880). Phosphorylation of the peptide was determined by Western blot using the anti-Thr³⁵⁰-MYPT1 antibody. Consistent with the results in Fig. 1C, ROCK kinase activity was enhanced in immunoprecipitates of PMA-treated LNCaP cells (Fig. 1D). Activation of ROCK by PMA was blocked by pretreatment of cells with the ROCK inhibitor Y-27632 (Fig. 1E), as expected, as well as by the pan-PKC inhibitor GF 109203X (Fig. 1F).
Rho GTPases are best known for their roles in the regulation of cytoskeleton rearrangement and the generation of the contractile force necessary for the formation of stress fibers (13). We first examined if PKC activation causes cytoskeleton reorganization in LNCaP cells. As shown in Fig. 1, PMA promotes the formation of stress fibers, and this effect was sensitive to the PKC inhibitor GF 109203X. Moreover, the ROCK inhibitor Y-27632 blocked the formation of stress fibers in response to PMA. Taken together, these results indicate that PMA is a strong activator of Rho and its downstream effector ROCK in LNCaP prostate cancer cells.

Rho and ROCK Are Implicated in PMA-induced Apoptosis—To determine whether Rho plays a role in PMA-induced apoptosis in LNCaP cells, we expressed a dominant negative RhoA mutant (N19-RhoA) by adenoviral means. As a control, we used a GFP AdV. Expression of N19-RhoA reduced the apoptotic effect of PMA by ~40% (Fig. 2A). Next, to determine if ROCK is implicated in PMA-induced apoptosis, we used the ROCK inhibitor Y-27632. As shown in Fig. 2B, the ROCK inhibitor significantly blocked PMA-induced apoptosis in LNCaP cells, suggesting a role for the Rho-ROCK pathway in phorbol ester-induced apoptosis. Y-27632 also blocked the apoptotic effect of PMA in C4-2 and CRW22 cells (supplemental Fig. S1).

PKCδ Mediates PMA-induced Activation of Rho and Stress Fiber Formation—Previous studies from our laboratory demonstrated that PMA-induced apoptosis is mediated by the acti-
this PKC is implicated in Rho activation by PMA. RhoA-GTP levels were determined in LNCaP cells subject to PKCδ RNAi, using two different RNAi duplexes (PKCδ RNAi-1 and PKCδ RNAi-2). PKCδ depletion was >75% with either RNAi duplex (Fig. 2C, left). Fig. 2C (right) shows that the activation of RhoA by PMA was greatly reduced in PKCδ-depleted LNCaP cells. We next assessed the effect of PKCδ knockdown on ROCK activation. As shown in Fig. 2D, PMA-induced activation of ROCK in LNCaP cells was impaired as a consequence of PKCδ RNAi depletion. To further assess the involvement of PKCδ in Rho function, we examined stress fiber formation in response to PMA in PKCδ-depleted cells. Fig. 2E shows that LNCaP cells subject to PKCδ RNAi failed to assemble stress fibers in response to the PKC activator. These observations indicate that activation of PKCδ in LNCaP cells promotes the activation of RhoA and RhoA-dependent responses via ROCK.

Cytoskeleton-dependent JNK Activation Is Required for PMA-induced Apoptosis—Our previous studies established that the apoptotic effect of phorbol esters is caused by the autocrine release of death factors, primarily TNFα and TRAIL, an effect mediated by PKCδ. CM collected from PMA-treated LNCaP cells has the ability to trigger an apoptotic response via the extrinsic cascade, which becomes activated in response to the death factors released to the CM. Although we found that inhibition of JNK does not affect the release of death factors (11), SP600126 blocked the apoptotic effect of CM from PMA-treated cells, suggesting a key role for the JNK pathway in the effect of the autocrine factors. CM collected from PMA-treated LNCaP cells causes a strong and sustained JNK activation when added to a previously untreated culture of LNCaP cells (11). Fig. 3A shows that the JNK inhibitor SP600126 caused a significant impairment of the PMA apoptotic response. The effect was observed when SP600126 was left in the medium after the PMA treatment but not if only added for short times after PMA treatment (data not shown) (28). These results are consistent with the involvement of JNK as a mediator of the effect of death factors but
Rho and ROCK as Mediators of PMA-induced Apoptosis

FIGURE 3. ROCK-mediated JNK activation is required for PMA-induced apoptosis. A, LNCaP cells were treated with SP600125 (20 μM), added 1 h before PMA (100 nm, 1 h) or vehicle (ethanol) treatment. The incidence of apoptosis was determined 24 h later. B and C, LNCaP cells were treated with Y-27632 (10 μM) (B), cytochalasin B (2 μM), or blebbistatin (50 μM) (C), added 1 h before PMA treatment. Cells were then treated with 100 nm PMA for the indicated times (B) or for 30 min (C), and phospho-JNK or total JNK levels were determined by Western blot. The -fold increase in phospho-JNK levels is shown below the corresponding Western blots. D, LNCaP cells were treated with cytochalasin B (2 μM) or blebbistatin (50 μM), added 1 h before PM or vehicle (ethanol) treatment. Cells were then treated with PMA (30–100 nm) or vehicle for 1 h. The incidence of apoptosis was determined 24 h later. Results are presented as mean ± S.D. (n = 3). Two additional experiments gave similar results.

not their release (11). It has been demonstrated in various cellular models that Rho and ROCK mediate JNK activation in response to stimuli (29–31). Therefore, we examined if ROCK is involved in JNK activation by PMA in LNCaP cells. As shown in Fig. 3B, the ROCK inhibitor Y-27632 markedly reduced JNK activation.

ROCK plays a major role in the assembly of actin stress fibers, which is required for membrane blebbing and nuclear disintegration and has been shown in some cases to be required for the execution of apoptosis (13–19). These effects are mediated by ROCK phosphorylation of myosin light chain and activation of its ATPase activity, thus increasing the actin-myosin force and cell contractility (15, 18). We therefore speculated that the cytoskeleton is implicated in apoptosis triggered by PKCδ activation. To address this issue, we used the actin-destabilizing agent cytochalasin B and the myosin II inhibitor blebbistatin. As shown in Fig. 3C, although cytochalasin B or blebbistatin did not cause any measurable apoptotic response by themselves, they markedly inhibit PMA-induced apoptosis in LNCaP cells. This suggests that cytoskeleton rearrangement in response to PMA activation is required for the apoptotic effect of the phorbol ester in LNCaP prostate cancer cells. Furthermore, the cytoskeleton inhibitors cytochalasin B and blebbistatin also blocked JNK activation by PMA (Fig. 3D). Inhibition of cytoskeleton reorganization did not impair PKCδ activation, as determined by the lack of effect of blebbistatin on PKCδ translocation (supplemental Fig. S2). Taken together, these results indicate that ROCK regulates apoptosis through the activation of the JNK pathway through a cytoskeleton-dependent mechanism.

ROCK-mediated p21Cip1 up-regulation is required for apoptosis—It is noteworthy that in many cell types, PKC activation leads to the induction of the cell cycle inhibitor p21Cip1, which plays a central role in PMA-induced cell cycle arrest and senescence. This induction could be either p53-dependent or p53-independent, depending upon the cell type and stimuli (4, 32, 33). Studies have shown that p21Cip1 up-regulation preceded apoptosis induced by PMA in prostate cancer cells. To determine whether a causal relationship between p21Cip1 and PMA-induced apoptosis exists, we knocked down p21Cip1 using two different RNAi duplexes (p21 RNAi-a and p21 RNAI-b). A significant depletion in p21Cip1 levels was observed by delivery of either RNAi duplex into LNCaP cells (Fig. 4A). In LNCaP cells subjected to p21Cip1 RNAI, the induction of this cell cycle inhibitor was significantly attenuated, although full inhibition of p21Cip1 up-regulation could not be achieved (~70–80% depletion). Knockdown of p21Cip1 led to a reduced PMA apoptotic response (Fig. 4B). The effect was partial, which may suggest a partial requirement for p21Cip1 or otherwise relate to the residual p21Cip1 induction by the phorbol ester. The requirement of p21Cip1 for phorbol ester-induced apoptosis prompted us to investigate whether this effect was ROCK-mediated. We therefore examined the effect of Y-27632 on p21Cip1 induction. Fig. 4C shows that PMA treatment caused a time-dependent induction of p21Cip1 in LNCaP cells. This induction was markedly reduced in the presence of the ROCK inhibitor (see also Fig. 4E). To determine whether p21Cip1 up-regulation by PMA is dependent upon the cytoskeleton rearrangement, we examined the effect of cytochalasin B and blebbistatin. Interestingly, both cytoskeleton inhibitors prevented p21Cip1 up-regulation by the phorbol ester (Fig. 4D). The induction of p21Cip1 by PMA was not affected by the JNK inhibitor SP600125 (Fig. 4E), suggesting that JNK activation and p21Cip1 induction downstream of Rho/ROCK are implicated in parallel mechanisms rather than in a linear pathway.

ROCK regulates p21Cip1 at a transcriptional level—Expression of p21Cip1 is controlled both by transcriptional and post-transcriptional mechanisms, including in response to PMA (4, 32, 33). Previous studies from our laboratory established a key role for PKCδ in p21Cip1 induction. PMA caused a marked ele-
ROCK Regulates TNFα Secretion in a JNK-independent Manner—Previous studies from our laboratory demonstrated that PMA-induced apoptosis of LNCaP cells is triggered by the autocrine secretion of death factors via PKC, with the subsequent ROCK-mediated p21Cip1 up-regulation being required for PMA-induced apoptosis.

To determine whether p21Cip1 induction by PMA has a transcriptional component, we carried out a gene reporter assay using a p21Cip1 promoter luciferase reporter. LNCaP cells were transfected with the p21Cip1 reporter vector p21P (25), which encodes a fragment comprising bp −1 to −2400 in the human p21Cip1 promoter fused to firefly luciferase. A Renilla luciferase vector was co-transfected for normalization of transfection efficiency. As shown in Fig. 5A, PMA treatment led to a marked increase in luciferase activity. Treatment with either Y-27632 or cytochalasin inhibited luciferase activity to a great extent.

Transcriptional activation of p21Cip1 is mediated through multiple mechanisms. Among the most relevant transcription factors, p53 and Sp1 have been widely implicated in transcriptional control of the p21Cip1 promoter (32, 34, 35). We used two deletion mutants of the human p21Cip1 promoter. The first mutant (p21PSma) has a deletion in bp −114 to −2400, which comprises the p53-responsive element in the promoter. The second mutant (p21PSmaΔ1) has the four Sp1 elements deleted (deletion in bp −49 to −114). Notably, although deletion of the large fragment that includes the p53-binding site caused only a minimal effect, deletion of the Sp1-responsive element abrogated the induction of luciferase activity by PMA (Fig. 5B). To demonstrate the involvement of Sp1 in p21Cip1 induction, we used RNAi to knock down endogenous Sp1. We used two RNAi sequences: Sp1 RNAi-1, which depleted endogenous Sp1 by 80%, and Sp1 RNAi-2, which was less efficient (Fig. 5C, left). We found that Sp1 RNAi-1 significantly blocked p21Cip1 up-regulation, whereas Sp1 RNAi-2 had only a marginal effect (Fig. 5C, right). These results suggest that the induction of p21Cip1 by PMA is mediated by Sp1-dependent mechanisms and independent of p53, despite the fact that LNCaP cells have functional p53.
quent activation of the extrinsic apoptotic cascade. Among the death factors, TNFα is the most relevant one. JNK was identified as a mediator of the TNFα effect (11). To examine whether ROCK regulates TNFα secretion via JNK, we compared TNFα secretion in conditioned medium from LNCaP cells treated with PMA in the absence or presence of the ROCK inhibitor Y-27632 or the JNK inhibitor SP600125. As shown in Fig. 6A, ROCK inhibitor markedly inhibited TNFα secretion, whereas the JNK inhibitor had no effect. These results suggest that ROCK regulates TNFα secretion in a JNK-independent manner.

**DISCUSSION**

Despite the well-established role for PKC in mitogenesis and tumor promotion, considerable evidence supports the involvement of discrete PKC isozymes in growth inhibition and apoptosis. Phorbol esters exert profound effects on the machinery that controls the cell cycle and modulate in either positive or negative manners multiple signaling pathways implicated in proliferation, survival, and apoptosis. In that regard, studies by our laboratory and others have established a prominent role for PKCδ, a member of the novel PKC family, as a mediator of growth inhibition and apoptosis in response to phorbol esters (4–8, 11, 28). Androgen-dependent prostate cancer cells, such as LNCaP and CWR22-Rv1 cells, undergo apoptosis in response to phorbol esters via activation of PKCδ-driven apoptosis are only partially understood. Previous studies from our laboratory established key roles for the JNK cascade as a mediator of phorbol ester-induced apoptosis in LNCaP cells (11, 28). A more detailed analysis established that apoptosis is triggered by the autocrine secretion of death factors from prostate cancer cells via PKCδ, including TNFα and TRAIL, with the subsequent activation of the extrinsic apoptotic cascade. Interfering with death receptor signaling either by inhibition/depletion of TNFα/TRAIL receptors, RNAi depletion of the adaptor FADD or caspase-8, or pharmacological inhibition of p38 MAPK and JNK pathways in all cases impairs phorbol ester-induced apoptosis (11).

A distinctive aspect of the present study is the identification of the Rho-ROCK-p21cip1 pathway as an effector of PMA-induced apoptosis, which provides an additional layer of complexity and argues for the involvement of an intricate network of signaling cascades in this effect. Our results provide evidence that PMA induces RhoA and ROCK activation as well as the formation of stress fibers in
Rho and ROCK as Mediators of PMA-induced Apoptosis

LCaP prostate cancer cells via ROCK. The activation of the Rho pathway and cytoskeletal organization by PMA is mediated by PKCδ. Both the pan-PKC inhibitor GF 109203X and PKCδ RNAi depletion block RhoA activation and stress fiber formation. PKC isozymes have been implicated in Rho activation in several models, including cardiomyocytes (36), myoblasts (37), and endothelial cells (38). Although the mechanistic basis of PKCδ modulation of Rho/ROCK function in LCaP still remains to be elucidated, it has been shown that phorbol esters can activate Rho GTPases through different mechanisms that involve either Rho-GEF activation or Rho-GDI inactivation (22, 23). Rho-GEFs are a very diverse family, with >70 members being identified in humans (39). Studies have shown that PMA-induced apoptosis in erythroblastic D2 cells involves the RhoA-GEF GEF-H1. Depletion of GEF-H1 leads to a significant reduction of RhoA activity and prevents cells from undergoing PMA-induced apoptosis via the Rho-ROCK pathway (22). Studies in vascular smooth muscle cells revealed that Rho-dependent migration and JNK activation induced by angiotensin II were inhibited by the PKCδ inhibitor rottlerin or a dominant negative PKCδ mutant. PKCδ-dependent Rho/ROCK activation in these cells possibly involves PDZ-RhoGEF (40). There is also evidence that a PKC phosphorylation site in Rho-GDI modulates its association/dissociation from RhoA by changing the affinity for the small G-protein. Upon phosphorylation in Ser56, Rho-GDI dissociates from RhoA, thereby enabling RhoA activation in response to stimuli (23). Conceivably, PKCδ may also regulate the activity of Rho-GAPs and control the rate of GTP hydrolysis from the GTPase. For example, phorbol esters stimulate the phosphorylation of the Rho-GAP DLC1, leading to its relocalization and suppression of GAP activity. Several studies have also reported a physical association between PKCs and RhoA (24, 41). Although there is very limited information regarding the expression and regulation of Rho-GEFs in prostate cancer cells, it is conceivable that mechanisms such as those described above and/or alternative yet unknown mechanisms may operate in prostate cancer cells, which requires further investigation, since they should provide relevant information on how PKCδ modulates RhoA in the context of apoptotic responses. Candidate Rho GEFs include Vav3, which has been implicated in prostate cancer progression (42), as well as LARG and PDZ-Rho-GEF, which mediate downstream Rho signaling in prostate cancer models (43, 44).

ROCK is a major regulator of cytoskeleton reorganization in response to stimuli. Studies have implicated the Rho/ROCK pathway in apoptosis in various cell models, including prostate cancer cells (19, 45), and established links between cytoskeleton remodeling and apoptosis programming or execution (17–19). ROCK has been implicated in myosin light chain phosphorylation and membrane blebbing as well as in Golgi fragmentation during apoptosis (47, 48). It is also known that ROCK modulates the extrinsic apoptotic cascade, which mediates PMA-induced apoptosis in LNCaP prostate cancer cells via the autocrine release of death factors and activation of caspase-8 (11). Studies in a paradigm of PMA-induced apoptosis in erythroblastic TF-1 cells implicated ROCK in the formation of DISC complex (19). Interestingly, we also found that ROCK inhibition prevents the release of death factors from LNCaP cells in response to PMA (data not shown). Since this release of death factors is entirely dependent on PKCδ (11), we speculate that ROCK is also downstream of PKCδ in the regulation of the autocrine response. Studies have shown that the cytoskeleton is involved in the extrinsic apoptotic cascade, since it controls DISC formation and modulates the localization of key components of the cascade, including death receptors (49–51). The Rho pathway also controls transcriptional mechanisms via cytoskeleton-dependent and -independent processes (29, 52, 53), and a ROCK-dependent transcriptome has been recently defined, which includes genes involved in cytoskeletal reorganization (54). Actin polymerization modulates the activity of RNA polymerases and has been also implicated in chromatin remodeling as well, since it serves as a platform for the transcriptional recruitment and/or tethering of histone-modifying enzymes via its association with pre-mRNPs (55). Interestingly, in PMA-treated prosapoptotic D2 cells, two nuclear restricted pre-mRNA binding proteins, heterogeneous nuclear
Rho and ROCK as Mediators of PMA-induced Apoptosis

ribonucleoprotein C1 and C2, are translocated to the cytosolic compartment in a ROCK-dependent manner (56). Notably, analysis of PKC-regulated genes in LNCaP cells revealed a number of Rho-GEFs that become up-regulated in response to PMA, including ARHGEF2, ARHGEF10, and ARHGEF12, as well as Rho-GAPs that become down-regulated, such as ARHGAP11a and ARHGAP19. The relative contributions of these Rho effectors in prostate cancer cells still need to be determined.

Our studies also implicate the cell cycle inhibitor p21\(^{\text{Cip1}}\) as a mediator of PMA-induced apoptosis in prostate cancer cells. It is well established that in many cell types, PMA stimulation leads to the induction of p21\(^{\text{Cip1}}\), and this induction plays a central role in PMA-induced growth inhibition (4, 5). Previous studies from our laboratory in lung cancer cells showed that PKC\(\delta\) controls p21\(^{\text{Cip1}}\) up-regulation at a transcriptional level, whereas other PKCs are less important for controlling the expression of this cell cycle inhibitor (4). Early studies established that p21\(^{\text{Cip1}}\) induction and retinoblastoma dephosphorylation preceded PMA-induced apoptosis in LNCaP cells (10). We found that impeding p21\(^{\text{Cip1}}\) induction using RNAi attenuates cell death in response to the phorbol ester. Recently, studies in prostate and colon cancer cell lines showed that p21\(^{\text{Cip1}}\) up-regulation is essential for TRAIL sensitization by proteasome inhibitors (57) and HDAC inhibitors (58), highlighting the relevance of this cell cycle inhibitor in sensitizing for cell death induced by cyto- kines, as suggested by our studies. We also determined that p21\(^{\text{Cip1}}\) up-regulation by PMA is ROCK-dependent. The regulation of p21\(^{\text{Cip1}}\) by Rho family members is controversial, since Rho was found to either suppress or induce the expression of cell cycle inhibitors, depending on the cell type (59–61). In contrast to our studies in prostate cancer cells, PMA-treated D2 erythromyeloblasts, the proapoptotic population has impaired p21\(^{\text{Cip1}}\) up-regulation resulting from ROCK activation, suggesting major cell type differences in the control of the pathway. JNK has been also linked to p21\(^{\text{Cip1}}\) expression (62). However, although in LNCaP cells JNK activation is ROCK-dependent, a JNK inhibitor does not abrogate p21\(^{\text{Cip1}}\) induction, suggesting the involvement of parallel pathway(s). Although p21\(^{\text{Cip1}}\) up-regulation in some cell types is dependent upon the activation of the MEK-ERK pathway (60), Y-27632 did not affect ERK phosphorylation by PMA in LNCaP cells (data not shown), suggesting that in our model, ROCK regulation of p21\(^{\text{Cip1}}\) is ERK-independent. Indeed, our previous studies showed that a MEK inhibitor enhances PMA-induced apoptosis (28). A p38 inhibitor also failed to impair p21\(^{\text{Cip1}}\) induction by PMA in LNCaP cells (data not shown). Although MAPK cascades exert transcriptional effects via Sp1 transcription factors, deletion of Sp1 sites in the human p21\(^{\text{Cip1}}\) promoter abrogates the induction by PMA. As PMA exerts pleiotropic effects on signaling cascades, it is conceivable that MAPK-independent pathways modulate p21\(^{\text{Cip1}}\) transcriptional activation, such as direct phosphorylation of Sp1 by protein kinase G, cyclin-dependent kinases, or other kinases (46, 63, 64).

In summary, our studies showed that RhoA/ROCK and the cytoskeleton are implicated in PMA-induced apoptosis in prostate cancer cells. A key role for the cell cycle inhibitor p21\(^{\text{Cip1}}\) has also been identified in the context of Rho signaling. A model summarizing our findings is depicted in Fig. 6B. A considerable amount of effort has been devoted to developing PKC modulators with anti-cancer therapeutic value, although selective agonists for PKC\(\delta\) as antiangiogenic/proapoptotic agents have yet to be developed. The elucidation of the PKC\(\delta\) downstream effectors is highly relevant to understanding the basis of cell growth inhibition and apoptosis mediated by this kinase. The identification of Rho/ROCK as a mediator of PKC\(\delta\)-driven apoptosis may provide a novel platform for the design of PKC modulators for cancer treatment.

REFERENCES

1. Newton, A. C. (2001) Chem. Rev. 101, 2353–2364
2. Griner, E. M., and Kazanietz, M. G. (2007) Nat. Rev. Cancer 7, 281–294
3. Barry, O. P., and Kazanietz, M. G. (2001) Curr. Pharm. Des. 7, 1725–1744
4. Nakagawa, M., Oliva, J. L., Kothapalli, D., Fournier, A., Assoian, R. K., and Kazanietz, M. G. (2005) J. Biol. Chem. 280, 33926–33934
5. Black, J. D. (2000) Front. Biosci. 5, D406–D423
6. Afsariabi, E., Ahlgren, I., Bergelin, N., and Törnquist, K. (2008) Mol. Cell. Endocrinol. 292, 26–35
7. Fujii, T., García-Bermejo, M. L., Bernabó, J. L., Caamaño, J., Obha, M., Kuroki, T., Li, L., Yuspa, S. H., and Kazanietz, M. G. (2000) J. Biol. Chem. 275, 7574–7582
8. Yin, L., Bennani-Baiti, N., and Powell, C. T. (2005) J. Biol. Chem. 280, 5533–5541
9. Truman, J. P., Gueven, N., Lavin, M., Leibel, S., Kolesnick, R., Fuchs, Z., and Haimovitz-Friedman, A. (2005) J. Biol. Chem. 280, 23262–23272
10. Zhao, X., Gschwend, J. E., Powell, C. T., Foster, R. G., Day, K. C., and Day, M. L. (1997) J. Biol. Chem. 272, 22751–22757
11. Gonzalez-Guerrico, A. M., and Kazanietz, M. G. (2005) J. Biol. Chem. 280, 38982–38991
12. Xiao, L., Gonzalez-Guerrico, A., and Kazanietz, M. G. (2009) Mol. Carcinog. 48, 187–195
13. Jaffe, A. B., and Hall, A. (2005) Annu. Rev. Cell Dev. Biol. 21, 247–269
14. Etienne-Manneville, S., and Hall, A. (2002) Nature 420, 629–635
15. Riento, K., and Ridley, A. J. (2003) Nat. Rev. Mol. Cell. Biol. 4, 446–456
16. Shi, J., and Wei, L. (2007) Arch. Immunol. Ther. Exp. 55, 61–75
17. Coleman, M. L., Sahai, E. A., Yeo, M., Bosch, M., Dewar, A., and Olson, M. F. (2001) Nat. Cell Biol. 3, 339–345
18. Sebbagh, M., Renvoizé, C., Hamelin, J., Riché, N., Bertoglio, J., and Bréard, J. (2001) Nat. Cell Biol. 3, 346–352
19. Lai, J. M., Hsieh, C. L., and Chang, Z. F. (2003) J. Cell Sci. 116, 3491–3501
20. Del Re, D. P., Miyamoto, S., and Brown, J. H. (2007) J. Biol. Chem. 282, 8069–8078
21. Pan, Q., Tao, L., W., Teknos, T. N., and Merajver, S. D. (2006) Cancer Res. 66, 9379–9384
22. Chang, Y. C., Lee, H. H., Chen, Y. J., Bokoch, G. M., and Chang, Z. F. (2006) Cell Death Differ. 13, 2023–2032
23. Mehta, D., Rahman, A., and Malik, A. B. (2001) J. Biol. Chem. 276, 22614–22620
24. Slater, S. I., Seiz, J. L., Stagliano, B. A., and Stubbs, C. D. (2001) Biochemistry 40, 4437–4445
25. De Sierro, A., Marinissen, M., Digs, J., Wang, X. F., Pages, G., and Senden- wiercz, A. (2004) Cancer Res. 64, 743–750
26. Ren, X. D., and Schwartz, M. A. (2000) Methods Enzymol. 325, 264–272
27. Liu, P. Y., and Liao, J. K. (2008) Methods Enzymol. 439, 181–189
28. Tanaka, Y., Gavrielides, M. V., Mitsuuchi, Y., Fujii, T., and Kazanietz, M. G. (2003) J. Biol. Chem. 278, 33753–33762
29. Marinissen, M. J., Ciarrello, M., Tanos, T., Bernard, O., Narumiya, S., and Gutkind, J. S. (2004) Mol. Cell. 14, 29–41
30. Potin, S., Bertoglio, J., and Bréard, J. (2007) FEBS Lett. 581, 118–124

4 V. Von Burstin, M. C. Caino, and M. G. Kazanietz, unpublished observations.
31. Unterseher, F., Hefele, J. A., Giehl, K., De Robertis, E. M., Wedlich, D., and Schambony, A. (2004) *EMBO J.* **23**, 3259–3269
32. Schavinsky-Khrapunsky, Y., Huleihel, M., Aboud, M., and Torgeman, A. (2003) *Oncogene* **22**, 3259–3269
33. Park, J. W., Jang, M. A., Lee, Y. H., Passaniti, A., and Kwon, T. K. (2001) *Biochem. Biophys. Res. Commun.* **280**, 244–248
34. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) *Cell* **75**, 817–825
35. Gartel, A. L., and Tyner, A. L. (1999) *Exp. Cell Res.* **246**, 280–289
36. Pan, J., Singh, U. S., Takahashi, T., Oka, Y., Palm-Leis, A., Herbelin, B. S., and Baker, K. M. (2005) *J. Cell. Physiol.* **202**, 536–553
37. Meacci, E., Donati, C., Cencetti, F., Romiti, E., and Bruni, P. (2000) *FEBS Lett.* **482**, 97–101
38. Harrington, E. O., Shannon, C. J., Morin, N., Rowlett, H., Murphy, C., and Lu, Q. (2005) *Exp. Cell Res.* **308**, 407–421
39. Garcia-Mata, R., and Burridge, K. (2007) *Trends Cell Biol.* **17**, 36–43
40. Ohtsu, H., Mifune, M., Frank, G. D., Saito, S., Inagami, T., Kim-Mitsuyama, S., Takuwa, Y., Sasaki, T., Rothstein, J. D., Suzuki, H., Nakashima, H., Woolfolk, E. A., Motley, E. D., and Eguichi, S. (2005) *Arterioscler. Thromb. Vasc. Biol.* **25**, 1831–1836
41. Slater, S. J., Cook, A. C., Seiz, J. L., Malinowski, S. A., Stagliano, B. A., and Stubbs, C. D. (2003) *Biochemistry* **42**, 12105–12114
42. Lyons, L. S., and Burnstein, K. L. (2006) *Mol. Endocrinol.* **20**, 1061–1072
43. Wang, Q., Liu, M., Kozasa, T., Rothstein, J. D., Sternweis, P. C., and Neubig, R. R. (2004) *J. Biol. Chem.* **279**, 28831–28834
44. Chang, Z. F., and Lee, H. H. (2006) *J. Biomed. Sci.* **13**, 173–180
45. Papadopoulou, N., Charalampopoulos, I., Alevizopoulos, K., Gravanis, A., and Stournaras, C. (2008) *Exp. Cell Res.* **314**, 3162–3174
46. Chu, S., and Ferro, T. J. (2005) *Gene* **348**, 1–11
47. Mills, J. C., Stone, N. L., Erhardt, J., and Pittman, R. N. (1998) *J. Cell Biol.* **140**, 627–636
48. Orlando, K. A., and Pittman, R. N. (2006) *Exp. Cell Res.* **312**, 3298–3311
49. Cohen, O., Inbal, B., Kissil, J. L., Raveh, T., Berissi, H., Spivak-Kroizman, T., Feinstein, E., and Kimchi, A. (1999) *J. Cell Biol.* **146**, 141–148
50. Jin, Y., Atkinson, S. J., Marrs, J. A., and Gallagher, P. J. (2001) *J. Biol. Chem.* **276**, 30342–30349
51. Chaigne-Delalande, B., Moreau, J. F., and Legembre, P. (2008) *Arch. Immunol. Ther. Exp.* **56**, 9–14
52. Yanazume, T., Hasegawa, K., Wada, H., Morimoto, T., Abe, M., Kawamura, T., and Sasayama, S. (2002) *J. Biol. Chem.* **277**, 8618–8625
53. Marinissen, M. J., Chiariello, M., and Gutkind, J. S. (2001) *Genes Dev.* **15**, 535–553
54. Berenjen, I. M., and Bustelo, X. R. (2008) *Clin. Transl. Oncol.* **10**, 726–738
55. Miralles, F., and Visa, N. (2006) *Curr. Opin. Cell Biol.* **18**, 261–266
56. Lee, H. H., Chien, C. L., Liao, H. K., Chen, Y. J., and Chang, Z. F. (2004) *J. Cell Sci.* **117**, 5579–5589
57. Lashinger, L. M., Zhu, K., Williams, S. A., Shrader, M., Dinney, C. P., and McConkey, D. J. (2005) *Cancer Res.* **65**, 4902–4908
58. Navrocki, S. T., Carew, J. S., Douglas, L., Cleveland, J. L., Humphreys, R., and Houghton, J. A. (2007) *Cancer Res.* **67**, 6987–6994
59. Croft, D. R., and Olson, M. F. (2006) *Mol. Cell. Biol.* **26**, 4612–4627
60. Lai, J. M., Wu, S., Huang, D. Y., and Chang, Z. F. (2002) *Mol. Cell. Biol.* **22**, 7581–7592
61. Coleman, M. L., Densham, R. M., Croft, D. R., and Olson, M. F. (2006) *Oncogene* **25**, 2708–2716
62. Kim, C. G., Choi, B. H., Son, S. W., Yi, S. J., Shin, S. Y., and Lee, Y. H. (2007) *Cell. Signal.* **19**, 1290–1300
63. Cen, B., Deguchi, A., and Weinstein, I. B. (2008) *Cancer Res.* **68**, 5355–5362
64. Fojas de Borja, P., Collins, N. K., Du, P., Azizkhan-Clifford, J., and Mudryj, M. (2001) *EMBO J.* **20**, 5737–5747